Held by 3 specialist biotech funds
High Convergence# Signal Note: Perceptive Advisors Initiates SVRA Position Edelman's $14.5M entry into Savara likely reflects conviction in its lead program, mometasone for systemic sclerosis-associated interstitial lung disease (SSc-ILD), which has demonstrated clinical benefit in prior studies and is advancing toward potential regulatory milestones.
AI analyst context — unlock full analysis
# Signal Note: Deerfield Initiates $81.8M Position in SVRA Deerfield's substantial entry into Savara signals conviction in the company's rare pulmonary disease pipeline, most notably moeragcin alfa (MOA-004) for pulmonary alveolar proteinosis (PAP), which has generated positive Phase 2 data and is progressing toward late-stage development. The $81.8M stake (13.6M shares at ~$6/share) suggests confidence in near-term catalysts, likely including regulatory feedback or Phase 2b readout timing for MOA-004. This is a meaningful vote of confidence from a systematic healthcare investor with strong pattern recognition in specialty therapeutics.
+ 1more — see how much conviction went in
See the Full Story